NEW YORK, May 25, 2026, 15:04 (EDT)
ImmuCell Corporation shares were idle Monday with U.S. markets shut for Memorial Day. The animal-health stock is coming off a big rally last week and will reopen Tuesday. Nasdaq was closed May 25 for the holiday, and keeps regular hours from 9:30 a.m. to 4:00 p.m. Eastern on normal days.
ImmuCell (ICCC) ended Friday at $10.12, up 1.1%, and has added about 13.5% since last Friday’s close of $8.92. Shares surged 11.1% after earnings on Monday, May 18.
ICCC is thinly traded and has a small market cap. The stock’s market value stood at around $91.5 million. On Friday, trading volume was 33,470 shares, compared to 117,969 shares on May 18. A small amount of trading can move the price.
Immucell hasn’t put out a fresh press release since it reported first-quarter numbers back on May 14. The investor site is showing the next scheduled shareholder event is the annual meeting on June 11. So action this week looks set to depend on how the shares trade when markets reopen Tuesday, moves in the stock after that, and whether there’s any news about production capacity.
ImmuCell posted first-quarter product sales of $10.4 million, up 28.4% over last year. Gross margin increased to 45.0%. Net income climbed to $1.9 million, or 21 cents per share, compared with $1.4 million, or 16 cents, in the same quarter a year ago.
Chief Financial Officer Timothy C. Fiori said results for the quarter got a lift from “higher volumes, manufacturing efficiencies, and price realization.” The company reported cash was $6.8 million at March 31, up from $3.8 million at the end of the year.
ImmuCell sells First Defense for calf scours, also called neonatal calf diarrhea. The company’s 10-Q says First Defense is regulated in the U.S. as a veterinary biologic, an animal-health product made from biological sources. ImmuCell notes sales are seasonal, with Q1 often higher since most beef calving happens January through April.
Bobbi Brockmann, senior vice president of sales and marketing, said revenue “traditionally moderates mid-year.” CEO Olivier te Boekhorst said average monthly manufacturing output increased from around 380,000 units in 2025 to over 450,000 in the first quarter. He said the company is “laser-focused” on First Defense.
Production is the key figure for the stock here. On the call, te Boekhorst said earlier problems weren’t much about demand. Instead, she pointed to “manufacturing capacity and product availability.” The Motley Fool
Investors got a new figure in the balance sheet. ImmuCell reported a $2 million settlement payment from Norbrook Laboratories under a May 8 deal, tied to a past development and commercial supply contract. Management says it plans to use the cash for capacity expansion.
Elanco has Scour Bos for broad-spectrum scours, and Zoetis sells ScourGuard 4KC for pre-birth scours protection. ImmuCell is pushing First Defense as an oral antibody product, aiming to get traction as supplies increase.
The run in the stock could lose steam if investors think the solid first quarter is already priced in. ImmuCell is pointing to mid-year moderation, shifting customer orders, production expansion risk, and unpredictable weather changing demand for prevention products. International sales dropped 30.2% to roughly $600,000 in the first quarter.
So far, ImmuCell is still holding the gains. The stock jumped last week, but trading on Tuesday should clarify if that was just a squeeze into the holiday or if investors see a bigger shift as ImmuCell focuses tighter on First Defense.
